Press release
Benign Prostatic Hyperplasia Treatment Market Size, Demand, Competitive Analysis, Regional Growth and Forecast by 2026
According to IMARC Group's latest report, titled "Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026", the global benign prostatic hyperplasia treatment market reached a value of US$ 10.5 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 5.6% during 2021-2026.We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request a Free PDF Sample of the Report: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market/requestsample
Benign prostatic hyperplasia (BPH) refers to non-cancerous growth of the prostate gland that causes urethra blockage. This disorder generally results in the retention of urine, formation of bladder stones, incontinence due to overfilling, increased sensitivity of the bladder, and urinary tract infections. Some commonly used treatment methods for BPH include prescription drugs, mono drug and combination therapy, Phyto-therapies, and minimally-invasive (MI) and invasive surgeries. Resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants are some of the standard instruments used in BPH treatment surgeries.
Market Trends and Drivers:
The rising prevalence of urological disorders across the globe, coupled with the growing geriatric population, is currently driving the benign prostatic hyperplasia treatment market growth. Furthermore, the increasing consumer awareness towards the availability of efficient and minimally-invasive treatment procedures for BPH is also propelling the market. Moreover, various advancements in the medical sector have led to the development of transurethral resection of the prostate (TURP) as an efficient treatment technique. TURP is an endoscopic electrosurgical procedure that removes a portion of the prostate gland to reduce the obstruction caused by abnormal growth. In addition to this, the rising healthcare expenditures and improving healthcare infrastructures will continue to drive the market growth in the coming years.
Benign Prostatic Hyperplasia Treatment Market 2021-2026 Competitive Analysis and Segmentation:
Competitive Landscape With Key Players:
The competitive landscape of the benign prostatic hyperplasia treatment market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
Abbott Laboratories
GlaxoSmithKline Plc
Boston Scientific Corporation
Pfizer Inc.
Asahi Kasei Corporation
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Allergan Plc (AbbVie Inc.)
Astellas Pharma Inc.
Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
Key Market Segmentation:
The report has segmented the global benign prostatic hyperplasia treatment market on the basis of treatment and region.
Market Breakup by Treatment:
Drug Class
Alpha-Blockers
5-Alpha-reductase Inhibitors (5-ARIs)
Phosphodiesterase-5 Enzyme Inhibitors
Others
Minimally Invasive Surgeries
Transurethral Resection of the Prostate (TURP)
Transurethral Incision of the Prostate (TUIP)
Transurethral Microwave Thermotherapy (TUMT)
Robotic Surgeries
Prostatic Urethral Lifts
Others
Laser Therapy
Others
Market Breakup by Region:
North America
Asia Pacific
Europe
Latin America
Middle East and Africa
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=2898&flag=C
Key Highlights of the Report:
Market Performance (2015-2020)
Market Outlook (2021-2026)
Market Trends
Market Drivers and Success Factors
Impact of COVID-19
Value Chain Analysis
Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Benign Prostatic Hyperplasia Treatment Market Size, Demand, Competitive Analysis, Regional Growth and Forecast by 2026 here
News-ID: 2643148 • Views: โฆ
More Releases from IMARC Group

Saudi Arabia Gaming Market to Reach USD 4,738.5 Million by 2033, Industry Growin โฆ
๐๐๐ฎ๐๐ข ๐๐ซ๐๐๐ข๐ ๐๐๐ฆ๐ข๐ง๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ฏ๐๐ซ๐ฏ๐ข๐๐ฐ
๐๐๐ฌ๐ ๐๐๐๐ซ: 2024
๐๐ข๐ฌ๐ญ๐จ๐ซ๐ข๐๐๐ฅ ๐๐๐๐ซ๐ฌ: 2019-2024
๐
๐จ๐ซ๐๐๐๐ฌ๐ญ ๐๐๐๐ซ๐ฌ: 2025-2033
๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐ ๐ข๐ง ๐๐๐๐: ๐๐๐ ๐,๐๐๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง
๐๐๐ซ๐ค๐๐ญ ๐
๐จ๐ซ๐๐๐๐ฌ๐ญ ๐ข๐ง ๐๐๐๐: ๐๐๐ ๐,๐๐๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง
๐๐๐ซ๐ค๐๐ญ ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐๐ญ๐: ๐.๐% (๐๐๐๐-๐๐๐๐)
The Saudi Arabia gaming market was valued at ๐๐๐ ๐,๐๐๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง in 2024 and is projected to grow to ๐๐๐ ๐,๐๐๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง by 2033, with an expected compound annual growth rate (๐๐๐๐) ๐จ๐ ๐.๐% from 2025-2033.
๐๐๐ฎ๐๐ข ๐๐ซ๐๐๐ข๐ ๐๐๐ฆ๐ข๐ง๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ซ๐๐ง๐๐ฌ:
The gaming market in Saudiโฆ

UAE Health Insurance Market to Reach USD 14.9 Billion by 2033, Industry Growing โฆ
๐๐๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ฌ๐ฎ๐ซ๐๐ง๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐๐-๐๐๐๐
โข ๐๐๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ฌ๐ฎ๐ซ๐๐ง๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐ (๐๐๐๐): The UAE health insurance market size reached ๐๐๐ ๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง in 2024.
โข ๐๐๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ฌ๐ฎ๐ซ๐๐ง๐๐ ๐๐๐ซ๐ค๐๐ญ ๐
๐จ๐ซ๐๐๐๐ฌ๐ญ (๐๐๐๐): The market is expected to grow to ๐๐๐ ๐๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง by 2033.
โข ๐๐๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ฌ๐ฎ๐ซ๐๐ง๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐๐ญ๐: The market is anticipated to exhibit a ๐๐๐๐ ๐จ๐ ๐.๐% during the forecast period from 2025 to 2033.
๐๐๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ฌ๐ฎ๐ซ๐๐ง๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐ซ๐๐ง๐๐ฌ:
The market for health insuranceโฆ

Saudi Arabia Health Insurance Market to Reach USD 12.5 Billion by 2033, Industry โฆ
๐๐๐ฎ๐๐ข ๐๐ซ๐๐๐ข๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ฌ๐ฎ๐ซ๐๐ง๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐๐-๐๐๐๐
According to IMARC Group's report titled "๐๐๐ฎ๐๐ข ๐๐ซ๐๐๐ข๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ฌ๐ฎ๐ซ๐๐ง๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ฒ ๐๐ฒ๐ฉ๐ (๐๐ง๐๐ข๐ฏ๐ข๐๐ฎ๐๐ฅ, ๐๐ซ๐จ๐ฎ๐ฉ), ๐๐๐ซ๐ฏ๐ข๐๐ ๐๐ซ๐จ๐ฏ๐ข๐๐๐ซ (๐๐ฎ๐๐ฅ๐ข๐, ๐๐ซ๐ข๐ฏ๐๐ญ๐) ๐๐๐๐-๐๐๐๐", the report offers a comprehensive analysis of the industry, including market share, growth, trends, and regional insights.
๐๐จ๐ฐ ๐๐ข๐ ๐ข๐ฌ ๐ญ๐ก๐ ๐๐๐ฎ๐๐ข ๐๐ซ๐๐๐ข๐ ๐๐๐๐ฅ๐ญ๐ก ๐๐ง๐ฌ๐ฎ๐ซ๐๐ง๐๐ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ?
The Saudi Arabia health insurance market was valued at ๐๐๐ ๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง in 2024 and is projected to growโฆ

UAE Pharmaceutical Market Size Worth USD 8.02 Billion by 2033 | CAGR: 7.30%
๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ ๐๐๐ซ๐ค๐๐ญ ๐ข๐ง ๐๐๐ ๐๐๐๐:
๐๐จ๐ฐ ๐๐ข๐ ๐ข๐ฌ ๐ญ๐ก๐ ๐๐๐ ๐๐ก๐๐ซ๐ฆ๐๐๐๐ฎ๐ญ๐ข๐๐๐ฅ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ?
The UAE pharmaceutical market size was valued at ๐๐๐ ๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐. Looking forward, IMARC Group estimates the market to reach ๐๐๐ ๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, exhibiting a CAGR of ๐.๐๐% from 2025-2033.
๐๐๐ซ๐ค๐๐ญ ๐๐ญ๐๐ญ๐ข๐ฌ๐ญ๐ข๐
๐๐๐ฌ๐ ๐๐๐๐ซ: 2024
๐๐ข๐ฌ๐ญ๐จ๐ซ๐ข๐๐๐ฅ ๐๐๐๐ซ๐ฌ: 2019-2024
๐
๐จ๐ซ๐๐๐๐ฌ๐ญ ๐๐๐๐ซ๐ฌ: 2025-2033
๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐ ๐ข๐ง ๐๐๐๐: ๐๐๐ ๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง
๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐ ๐ข๐ง ๐๐๐๐: ๐๐๐ ๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง
๐๐๐ซ๐ค๐๐ญ ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐๐ญ๐ (๐๐๐๐) ๐๐๐๐-๐๐๐๐: ๐.๐๐%
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐
๐ซ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐โฆ
More Releases for Benign
Benign Prostatic Hyperplasia Therapeutics Market Clinical Survey Report 2020
The Benign Prostatic Hyperplasia Therapeutics Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Click the linkโฆ
Benign prostatic hyperplasia: BPH drugs versus Dr Allenโs Device
The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.
Thermobalancing therapy with Dr Allenโs Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allenโs Device.โฆ
Cold Plasma Market Benign Rate by 2025
Global Cold Plasma Market: Snapshot
Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasmaโordinarily known as the fourth condition of issueโwhich has gas particles show at direct temperature and electrons at moderately high temperatures. The properties of plasma have been widely looked into in the course of recent decades and an extensive number of front line utilizations of cold plasma innovation has exuded.
Cold plasma isn't inโฆ
Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, โฆ
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grantsโฆ
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
ReportsWorldwide has announced the addition of a new report title Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market to its growing collection of premium market research reports.
This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for BPH and prostatitis treatment devices.
Topics Covered Include:
An overview of device-based and pharmacological therapies for BPH and prostatitis.
Global and country/region-specific market forecasts, including forecasts by product segment.
Competitive analysesโฆ
Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2 โฆ
2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, aโฆ